Olema Pharmaceuticals, Inc. Logo

Olema Pharmaceuticals, Inc.

A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.

OLMA | US

Overview

Corporate Details

ISIN(s):
US68062P1066
LEI:
Country:
United States of America
Address:
780 BRANNAN STREET, 94103 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Operating as Olema Oncology, the company is dedicated to transforming the standard of care, with a primary focus on breast cancer. Its lead product candidate, palazestrant (OP-1250), is a novel, investigational agent being developed for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Olema's mission is to develop more effective and tolerable medicines to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Olema Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Olema Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Olema Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea 307750

Talk to a Data Expert

Have a question? We'll get back to you promptly.